BUZZ--You all will just crack up when you read this.>>
I had some shares, sold on the spike.
Thursday May 7, 1:56 pm Eastern Time
Company Press Release
Bradley Pharmaceuticals Anticipates Significant Sales
Increases for Lubrin Vaginal Moisturizer as a Result of the
Popularity of Viagra
FAIRFIELD, N.J.--(BUSINESS WIRE)--May 7, 1998--BRADLEY PHARMACEUTICALS, INC.
(NASDAQ NM: BPRX - news) foresees male Viagra(R) (Registered trademark of Pfizer, Inc.
NYSE: PFE) patients increased sexual drive significantly affecting female usage of Lubrin(R) Vaginal
Lubricant inserts. It is estimated in excess of 20 million post-menopausal women currently suffer from
vaginal dryness.
Many health-care experts share the view of Karin Martin, Sex Therapist at Hillside Hospital's
Sexuality Center in Lake Success, New York, who spoke about male patients in their mid 40's through
60's taking Viagra(R) and ''their partners are happy they are able to have a more complete sexual
relationship.'' Many other experts including Glenda Carle, author of ''Don't Bet on the Prince!'', state
that a number of women who have gone through menopause may have to use additional vaginal
lubricants.
Bradley Pharmaceuticals' reports increased sales for Lubrin(R) since the introduction of Viagra(R) and
expects sales to increase more with increased sexual activity among middle-aged Viagra(R) users and
their partners.
Lubrin(R) is a leading vaginal lubricant specifically designed to provide fast and prolonged lubrication
for vaginal dryness. It has been recommended for years by Obstetricians and Gynecologists as a
proven, safe and reliable form of personal lubrication which is odorless, colorless and non-staining.
Lubrin(R) which simulates the body's natural lubrication, is designed to be the most convenient,
non-messy vaginal lubricant available.
Lubrin(R), available without a prescription, is distributed nationally and available in independent
pharmacies as well as pharmacy chains such as: Walgreens, CVS and Eckerds.
BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products and
over-the-counter pharmaceuticals and health-related products throughout the United States as well as
in twenty-six international markets.
This release may contain forward-looking statements which reflect management's current views of
future events and operations. These forward-looking statements are based on assumptions and external
factors, including assumptions relating to regulatory action, capital requirements and competing
products. Any changes in such assumptions are external factors and could produce significantly
different results.
Contact:
Bradley Pharmaceuticals, Inc.
Daniel Glassman
Chairman and CEO
973/882-1505, Ext. 210
or
DeMonte Associates
Cynthia DeMonte
212/473-3700
e-mail: cdemonte@aol.com |
